'Partner with us to provide precision care at scale, ensuring that high-cost interventions like GLP-1s are used thoughtfully, effectively, and in a way that drives real outcomes.' LinkedIn ad: 'Most obesity care gets paid whether patients get healthier or not. We tie our revenue to whether our members do.'
Employers and health plans; members are covered employees/lives.
Outcomes-based contract pricing for employers/plans; no consumer prices published.
Precision obesity care combining drug access with connected devices, integrated medical records and lab data; 6- and 12-month outcome reporting for GLP-1 and non-GLP-1 pathways.
'Direct access to high-cost drugs at transparent, predictable price points' claimed; pharmacy not named.
Google 0; Meta 0; LinkedIn 1 genuine B2B ad with outcomes-based pricing message (20 Oct 2026). See dated channel evidence.
Not established in this pass.
Founder Elina Onitskansky, per the company's own LinkedIn ad naming 'Founder Elina Onitskansky'.
Not stated on pages reviewed.
Not assessed in this pass.